MedTrace Logo

Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)

NCT01354405 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2014-07-09

No results posted yet for this study

Summary

The aim of this study is to determine the effect of Lanreotide on polycystic liver and kidneys in patients with autosomal dominant polycystic kidney disease.

Conditions

  • Polycystic Liver Disease

Interventions

DRUG

Lanreotide

120 mg every 28 days intramuscular

Sponsors & Collaborators

  • Ipsen

    collaborator INDUSTRY

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Joost PH Drenth, MD, PhD · Radboud University Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01354405 on ClinicalTrials.gov